Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Director, Biologics Drug Discovery at Biogen
Paul Weinreb leads the Biologics Drug Discovery group at Biogen, where his team provides leadership and support to programs across all phases of Discovery and to early- and late-stage clinical and commercial programs that involve biologics modalities. He received his Ph.D. in Chemistry at the Massachusetts Institute of Technology followed by an NIH Postdoctoral Fellowship at Harvard Medical School. His ongoing research interests include the biochemistry of the integrin family of cell-surface receptors, and the role of protein aggregation in the etiology of neurodegenerative disease, and he has coauthored more than 70 peer-reviewed scientific publications. He is a co-inventor and led drug discovery efforts on several programs currently in clinical development, including aducanumab and BIIB076 for Alzheimer’s disease, BG00011 for idiopathic pulmonary fibrosis, and BIIB054 for Parkinson’s disease.